BioCam.ai
Primary tabs
About your organization / profile
About: BioCam is disrupting the $38B gastrointestinal track screening market by cutting the examination time by 90% and enabling remote diagnosis.
As BioCam, we want to popularize capsule endoscopy as a patient-friendly remote examination of the digestive system supported by AI algorithms and implement a new standard of digestive system screening for humans and animals.
BioCam’s proprietary technology is enabling at-home, patient-friendly and affordable procedures for humans & animals, improving early detection of dangerous diseases, e.g. colorectal cancer. Their AI-based software not only dramatically improves efficiency (minutes not hours), but also gives the doctors a clear yes/no answer to whether an actual colonoscopy is required with an F-Score of 97%! Their technology will be ready for commercial deployment on the veterinary market in the middle of 2025. Currently, BioCam is preparing for veterinary commercialization pilots and is in process 3-year distribution agreements with partners among others in Poland, Lithuania, Latvia , Italy, UK, Sweden, France, Brazil, in Africa (Tunisia, Algeria, Morocco, Nigeria), UAE and Saudi Arabia
IP: AI algorithms & proprietary hardware solution will be patented
Team: 30+ professionals, including renown AI experts in medical imaging, high-class microelectronics & microoptics engineers as well as experienced business professionals
Network (0)
There are no organizations in the network.
Recent activities
BioCam.ai has taken its fundraising offline.
BioCam.ai has published fundraising documents.
Maciej Wysocki has joined BioCam.ai.